Zealand Revenue

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;padding-top: 25px;;'>ZP</div>
ZEAL -- Denmark Stock  

DKK 241.40  3.60  1.47%

Zealand Pharma revenue fundamental analysis lookup allows you to check this and other indicators for Zealand Pharma AS or any other equity instrument. You can also select from a set of available indicators by clicking on the link to the right. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations. Please continue to Equity Screeners to view more equity screening tools

Search Revenue

 
Refresh
Revenue to Assets is projected to rize to 0.036447 this year. Revenue Per Employee is projected to rize to about 300.8 K this year.

Zealand Revenue Analysis

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and is an essential item when evaluating financial statements of a company. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
 2019 2020 (projected)
Long Term Debt to Equity0.2893910.297006
Interest Coverage54.2853.96
Zealand Pharma AS, a biotechnology company, engages in the discovery and development of peptide based medicines in Denmark. The company was founded in 1997 and is headquartered in Copenhagen, Denmark. Zealand Pharma operates under Biotechnology classification in Denmark and is traded on Copenhagen Stock Exchange. It employs 191 people.
Revenue 
 = 
Money Received 
Discounts and Returns 
More About Revenue | All Equity Analysis

Current Zealand Pharma AS Revenue

42.96 M

Zealand Distress Driver Correlations

Revenue Pattern

 Revenue to Assets 
      Timeline 

About Revenue

Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can includes product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Compare to competition

Zealand Pharma Revenue Related Assessment

  Revenue to Assets

Based on latest financial disclosure Zealand Pharma AS reported 42.96 M of revenue. This is 99.44% lower than that of the Healthcare sector, and 94.22% lower than that of Biotechnology industry, The Revenue for all stocks is 99.54% higher than the company.

Did you try this?

Run Portfolio Volatility Now

   

Portfolio Volatility

Check portfolio volatility and analyze historical return density to properly model market risk
All  Next Launch Module

Zealand PharmaCurrent Valuation Drivers

2014201520162017201820192020 (projected)
Revenue Per Employee1.49 M1.71 M1.89 M1.09 M254.88 K293.11 K300.82 K
PPandE Turnover7.9510.715.569.42.392.752.82
Receivables Turnover6.831.862.546.432.282.632.7
Return on Investment(17.485101)(14.919921)(19.674061)(38.659417)73.2865.9571.16
Cash Flow Per Share(1.864127)(9.475695)1.6(9.08349)(14.985709)(17.233565)(17.68708)
Revenue to Assets0.2576820.29570.3379920.1895930.0308810.0355130.036447
Quick Ratio7.478.323.899.1110.2711.8112.13
Receivables34.95 M167.23 M16.89 M26.61 M6.64 M5.98 M6.14 M
Accounts Payable18.49 M21.68 M19.74 M29.43 M32.65 M29.39 M31.71 M
Direct Expenses13.78 M22.27 M31.46 M14.63 M3.36 M3.02 M3.1 M

Zealand Fundamentals

About Zealand Pharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Zealand Pharma AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zealand Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zealand Pharma AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way. Please read more on our fundamental analysis page.

Current Sentiment - ZEAL

Zealand Pharma AS Investor Sentiment

Macroaxis portfolio users are unemotional in their take regarding investing in Zealand Pharma AS. What is your take regarding investing in Zealand Pharma AS? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Also Currentnly Active

<div class='circular--portrait-small' style='font-weight: 700;background:#FF0F00;color: #FFFFF0;font-size:1.1em;padding-top: 10px;;'>CI</div>
Purchased over 60 shares of
few hours ago
Traded for 44.1
<div class='circular--portrait-small' style='font-weight: 700;background:#347AFC;color: #ffffff;font-size:0.9em;padding-top: 12px;;'>VMW</div>
Purchased over 20 shares of
few hours ago
Traded for 134.6
<div class='circular--portrait-small' style='font-weight: 700;background:#4E8BFC;color: #ffffff;font-size:1.1em;padding-top: 10px;;'>SA</div>
Purchased few shares of
few hours ago
Traded for 177.85
Check out Zealand Pharma Piotroski F Score and Zealand Pharma Altman Z Score analysis. Please also try Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. drill down to check world indexes.


 
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page